MedTrace Logo

East New Britain Province Monitoring & Evaluation

NCT04124250 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12930

Last updated 2024-11-06

No results posted yet for this study

Summary

While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020 will be achieved. As of 2016, it was estimated that 856 million people are still living in areas with ongoing transmission of LF and require mass drug administration (MDA) \[1\]. Of the 52 countries that remain endemic and require MDA, 22 (42%) have not started MDA in all endemic implementation units (IUs) \[1\]. In addition, several countries have found that, despite completing the required number of treatment rounds, the response to the present MDA regimen has been suboptimal in some IUs, requiring additional rounds of MDA.

Conditions

  • Lymphatic Filariasis Elimination by Mass Drug Administration
  • Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
  • Acceptability of Mass Drug Administration for Lymphatic Filariasis

Interventions

OTHER

Observational

Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years

Sponsors & Collaborators

  • Case Western Reserve University

    collaborator OTHER

  • Washington University School of Medicine

    collaborator OTHER

  • Papua New Guinea Institute for Medical Research

    collaborator UNKNOWN

  • Papua New Guinea ENB Provincial Health Authority

    collaborator UNKNOWN

  • Papua New Guinea National Department of Health

    collaborator UNKNOWN

  • University Hospitals Cleveland Medical Center

    lead OTHER

Eligibility

Min Age
5 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-17
Primary Completion
2024-01-01
Completion
2024-01-01

Countries

  • Papua New Guinea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04124250 on ClinicalTrials.gov